Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
This invention concerns a new approach to the treatment of rheumatoid arthritis (RA) by "tolerogenic vaccination" with small interfering RNA (siRNA) technology. More
New pyridinic sulfonamide derivatives for the treatment and/or prevention of diseases such as inflammation, arthrosis, cancer and angiogenesis and for other pathologies in which they can play a role as COX-2 selective inhibitors. More
Methods of modulating PRMT-2 activity or expression in cells More
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models. More
Methods of administering N-acetylmannosamine or its derivative to treat muscular atrophy More
Experiments confirm that RPS3 is essential for normal expression of specific NF-kappaB target genes, including key physiological events that require p65. More
Novel agents that can interfere with the action of nuclear hormone receptors More
A monoclonal antibody that recognises a sub-population of neutrophils that are believed to be in the ‘late’ stages of apoptosis More
A monoclonal antibody that recognises a glycoprotein of unknown function on the surface of apoptotic neutrophils More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Cachexia
- Cervical dystonia
- Inflammation
- Muscular dystrophy
- Myasthenia gravis
- Spasticity
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us